Coronavirus vaccine: At present, over 170 coronavirus vaccines are under development stage and out of them, there are 5-6 vaccines that are expected to be available for civilian use by the first quarter of 2021. Let's take a look at these coronavirus vaccines.
The Post Graduate Institute of Medical Education and Research (PGIMER) in Chandigarh is among the 17 trial sites in India for conducting the second and third phases of human clinical trials of Covishield, the potential vaccine developed by Oxford University, its director said on Tuesday. The trials would involve administration of the vaccine to 1,600 healthy adults across 17 sites.
Adar Poonawalla, the CEO of Serum Institute of India (SII) which is manufacturing 20 crore — 200 million — doses of Oxford-AstraZeneca coronavirus vaccine and seeking phase 3 human trial approval from India's drug controller, says they hope to announce their own vaccine by the end of 2021.
Nationalist Congress Party (NCP) chief Sharad Pawar visited Serum Institute of India (SII) in Pune on Saturday afternoon. SII has signed an agreement to manufacture a potential coronavirus vaccine being developed by Jenner Institute of Oxford University in collaboration with British-Swedish pharma company AstraZeneca.
Coronavirus vaccine is an urgency for the world as COVID-19 cases continue to rise with the United States, Brazil, and India sharing the top 3 positions in terms of maximum cases of the infectious disease. As all vaccines are currently under trial stage, a look at where some of the leading vaccines stand at this point in time.
Serum Institute of India (SII), who earlier sought permission to conduct Phase 2 and 3 trials of Oxford University's coronavirus vaccine in India, has been advised to resubmit a revised protocol to carry out trials for the potential coronavirus vaccine.
Adar Poonawalla, CEO, Serum Institute of India (SII) said as per the arrangement with AstraZeneca, SII will be making one billion doses of Covishield vaccine over the next one year for India and other low-and-middle-income countries (GAVI countries).
Oxford University has reported satisfactory progress from the vaccines test results and is conducting bigger field tests in the UK. In India, it has chosen SII as manufacturing partner, which has to conduct field trials before getting the final nod to ensure they are safe and effective for Indians.
Oxford coronavirus vaccine, whose results of Phase I, II trials have appeared safe, will be called 'Covishield' in India, says Adar Poonawalla, CEO, Serum Institute of India, a Pune based manufacturing partner of AstraZeneca that will be producing 1 billion doses of the Oxford's corona vaccine.
Oxford-Astrazeneca joint collaboration vaccine is now a frontrunner in the race to find a shield immunity against COVID-19, the disease which has already infected over 15 million people worldwide. In a latest development, the vaccine is now being manufactured in the Pune based Serum Institute of India.
Amid speculations of researchers across the globe making great inroads into developing coronavirus vaccines, Serum Institute of India CEO, Adar Poonawalla has disclosed information on how much the vaccine could cost in India.
Team of scientists at Oxford Vaccine Group (Department of Paediatrics) and Oxford University’s Jenner Institute working on the discovery of a safe, effective and accessible vaccine against coronavirus have come out with the trial results that the world was waiting for. The results of Phase I/II trial published in the scientific journal, The Lancet, indicate no early safety concerns and induces strong immune responses.
Medical experts in India on Monday hailed the results of Oxford University's early-stage human trials for a COVID-19 vaccine, with some saying it's the "most scientifically done" among all such exercises, while others expressing hope that the final trials will "bear fruit".
The experimental coronavirus vaccine developed by AstraZeneca in collaboration with Oxford University has shown promising results and produced an immune response in part one of the two-phase clinical trials, a data was released on Monday.
The initial trial data for the COVID-19 vaccine that has been developed in a joint collaboration between Oxford University and AstraZeneca will be released today. The data has been widely awaited as the world looks forward to some good news on the front of a vaccine that could shield people from the deadly coronavirus outbreak that has already infected over 14 million people worldwide and killed over 6 lakh.
The esteemed Oxford University, which is working on the COVID-19 vaccine developed jointly by the university and AstraZeneca, will be releasing the data for the early stages of the human trials tomorrow. The Oxford university vaccine candidate is currently in the third phase of human trials that are being carried out in Brazil.
Last week, Spanish virologists announced the discovery of traces of the novel coronavirus in a sample of Barcelona waste water collected in March 2019, nine months before COVID-19 was identified in China.
The UK's biggest COVID-19 vaccine project, currently being tested by the The University of Oxford, has shown some promising results in a small study with monkeys.
Scientists from the University of Oxford have opened up their COVID-19 vaccines for clinical trial recruitments as part of a “rapid vaccine response” to the coronavirus pandemic.
The Oxford Hindi Word of the Year is a word or expression that has attracted a great deal of attention and reflects the ethos, mood, or preoccupations of the past year. It is also the Hindi translation of the word 'Constitution', an OUP statement said.
Top News
Latest News
